Clinical trials: Intravitreal Injection
Exudative Age-related Macular Degeneration
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet age-related macular degeneration.
- Trial name
- RAMEN (NCT04640272)
- Testing
- RBM-007
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ribomic USA Inc
Neovascular Age-related Macular Degeneration
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
The primary objective is to assess long-term safety and tolerability of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in patients with neovascular AMD.
- Trial name
- NCT00964795
- Testing
- Intravitreal Aflibercept Injection 2mg
- Where
- 124 sites in United States, Canada
- Volunteers
- 323 people
- Sponsor
- Regeneron Pharmaceuticals
Exudative Age-related Macular Degeneration
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
This is a multicenter, active-controlled, double masked study assessing the safety, efficacy and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four monthly RBM-007 injections in combination…
- Trial name
- TOFU (NCT04200248)
- Testing
- RBM-007 Injectable Solution, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 94 people
- Sponsor
- Ribomic USA Inc
Retinitis Pigmentosa
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
The primary objective of the study is to assess the safety of repeat injection of human retinal progenitor cells (jCell) in adult subjects with RP that have previously been treated with jCell.
- Trial name
- NCT04604899
- Testing
- human retinal progenitor cells
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- jCyte, Inc
Diabetic Macular Edema
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
To assess the safety of repeated iCo-007 intravitreal injections in treatment of subjects with diabetic macular edema as monotherapy and in combination with ranibizumab or laser photocoagulation To assess the change in visual…
- Trial name
- iDEAL (NCT01565148)
- Testing
- iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Johns Hopkins University
Vitreomacular Traction
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with vitreomacular traction.
- Trial name
- NCT00435539
- Testing
- ocriplasmin
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 60 people
- Sponsor
- ThromboGenics
Geographic Atrophy
A Study of NGM621 in Participants With Geographic Atrophy
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
- Trial name
- CATALINA (NCT04465955)
- Testing
- NGM621
- Where
- 65 sites in United States
- Volunteers
- 320 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Retinopathy of Prematurity (ROP)
Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy
The purpose of this study is to demonstrate how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies, and describe…
- Trial name
- FIREFLEYE (NCT04004208)
- Testing
- Eylea (Aflibercept, BAY86-5321), Laser photocoagulation
- Where
- 90 sites in Argentina, Austria and 25 more
- Volunteers
- 113 people
- Sponsor
- Bayer
Adverse Effect of Radiation Therapy
Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy
The primary objective of the study is to assess the safety of intravitreal aflibercept injection in treating visually compromising radiation maculopathy secondary to treatment of uveal melanoma by iodione-125 brachytherapy.
- Trial name
- NCT02586727
- Testing
- aflibercept
- Volunteers
- 40 people
- Sponsor
- Larkin Community Hospital
Leber Hereditary Optic Neuropathy
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
This study is meant to assess the safety and efficacy of rAAV2-ND4 treatment of Leber hereditary optic neuropathy with 11778 LHON mutation.
- Trial name
- rAAV2-ND4 (NCT01267422)
- Testing
- rAAV2-ND4
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Bin Li
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the…
- Trial name
- NCT01580020
- Testing
- RFB002, Dexamethasone
- Where
- 37 sites in Germany
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration (nAMD)
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.
- Trial name
- NCT05282004
- Testing
- SOK583A1
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sandoz
Vitreomacular Adhesion
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
The objective of this trial is to evaluate the safety and efficacy of intravitreal microplasmin 125µg dose in subjects wiht focal vitreomacular adhesion.
- Trial name
- NCT00781859
- Testing
- 125 µg Ocriplasmin
- Where
- 41 sites in United States
- Volunteers
- 326 people
- Sponsor
- ThromboGenics
Macular Edema
Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.
To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.
- Trial name
- AQUA (NCT02581995)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 76 sites in Austria, Canada and 12 more
- Volunteers
- 560 people
- Sponsor
- Bayer
Symptomatic Vitreomacular Adhesion
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
- Trial name
- NCT01889251
- Testing
- Ocriplasmin
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Alcon Research
Diabetic Macular Edema, Visual Impairment
Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema
This study will assess the efficacy and safety of ranibizumab (intravitreal injections) versus laser treatment in patients with visual impairment due to diabetic macular edema.
- Trial name
- RED-ES (NCT00901186)
- Testing
- RFB002, Laser photocoagulation
- Where
- 17 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant after 6 months of treatment. In the study arm Ranibizumab will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion
- Trial name
- COMRADE-B (NCT01396057)
- Testing
- Ranibizumab, Dexamethasone Implant
- Where
- 66 sites in Czechia, Germany and 3 more
- Volunteers
- 244 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Age-Related, Geographic Atrophy
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic…
- Trial name
- NCT04607148
- Testing
- Galegenimab
- Where
- 48 sites in United States
- Volunteers
- 144 people
- Sponsor
- Genentech, Inc.
AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)
To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD
This is an open label study to evaluate intravitreally administered 2.0 mg intravitreal aflibercept injection in patients who have been previously treated for AMD and have persistent or recurrent fluid despite monthly…
- Trial name
- NCT01495221
- Testing
- Alfilbercept
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Vitreous -Retina- Macula Consultants of New York